| Title |
SEOM clinical guideline for treatment of kidney cancer (2017)
|
|---|---|
| Published in |
Clinical and Translational Oncology, November 2017
|
| DOI | 10.1007/s12094-017-1765-4 |
| Pubmed ID | |
| Authors |
E. Gallardo, M. J. Méndez-Vidal, J. L. Pérez-Gracia, J. M. Sepúlveda-Sánchez, M. Campayo, I. Chirivella-González, X. García-del-Muro, A. González-del-Alba, E. Grande, C. Suárez |
| Abstract |
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 6 | 75% |
| Unknown | 2 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 88% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 81 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 15% |
| Student > Postgraduate | 9 | 11% |
| Researcher | 8 | 10% |
| Other | 7 | 9% |
| Student > Bachelor | 6 | 7% |
| Other | 13 | 16% |
| Unknown | 26 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 31% |
| Biochemistry, Genetics and Molecular Biology | 8 | 10% |
| Nursing and Health Professions | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 6 | 7% |
| Unknown | 31 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2018.
All research outputs
#5,916,030
of 23,016,919 outputs
Outputs from Clinical and Translational Oncology
#243
of 1,321 outputs
Outputs of similar age
#95,881
of 325,972 outputs
Outputs of similar age from Clinical and Translational Oncology
#9
of 41 outputs
Altmetric has tracked 23,016,919 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,321 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,972 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.